<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Dermatol</journal-id><journal-id journal-id-type="pmc-domain-id">4421</journal-id><journal-id journal-id-type="pmc-domain">jmirderm</journal-id><journal-id journal-id-type="publisher-id">JDERM</journal-id><journal-title-group><journal-title>JMIR Dermatology</journal-title></journal-title-group><issn pub-type="epub">2562-0959</issn><publisher><publisher-name>JMIR Publications Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10334943</article-id><article-id pub-id-type="pmcid-ver">PMC10334943.1</article-id><article-id pub-id-type="pmcaid">10334943</article-id><article-id pub-id-type="pmcaiid">10334943</article-id><article-id pub-id-type="pmid">37632892</article-id><article-id pub-id-type="doi">10.2196/38783</article-id><article-id pub-id-type="publisher-id">v5i4e38783</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="article-type"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Phenotype Algorithms to Identify Hidradenitis Suppurativa Using Real-World Data: Development and Validation Study</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Dellavalle</surname><given-names initials="R">Robert</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Sivesind</surname><given-names initials="T">Torunn</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Gulliver</surname><given-names initials="S">Susanne</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Feldman</surname><given-names initials="S">Steven</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Steingrimsson</surname><given-names initials="S">Steinn</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Hardin</surname><given-names initials="J">Jill</given-names></name><degrees>MBA, MS, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2682-2187</contrib-id><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><address><institution>Janssen Research and Development</institution><addr-line>1125 Trenton-Harbourton Road</addr-line><addr-line>Titusville, NJ, 08560</addr-line><country>United States</country><phone>1 650 619 8599</phone><email>jhardi10@its.jnj.com</email></address></contrib><contrib id="contrib2" contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Murray</surname><given-names initials="G">Gayle</given-names></name><degrees>MSW</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3685-269X</contrib-id></contrib><contrib id="contrib3" contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Swerdel</surname><given-names initials="J">Joel</given-names></name><degrees>MS, MPH, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9491-2737</contrib-id></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Janssen Research and Development</institution>
<addr-line>Titusville, NJ</addr-line>
<country>United States</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Observational Health Data Sciences and Informatics</institution>
<addr-line>New York, NY</addr-line>
<country>United States</country>
</aff><author-notes><corresp>Corresponding Author: Jill Hardin <email>jhardi10@its.jnj.com</email></corresp></author-notes><pub-date pub-type="collection"><season>Oct-Dec</season><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2022</year></pub-date><volume>5</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">440485</issue-id><elocation-id>e38783</elocation-id><history><date date-type="received"><day>15</day><month>4</month><year>2022</year></date><date date-type="rev-request"><day>29</day><month>6</month><year>2022</year></date><date date-type="rev-recd"><day>9</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>18</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-28 09:25:10.000"><day>28</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169;Jill Hardin, Gayle Murray, Joel Swerdel. Originally published in JMIR Dermatology (http://derma.jmir.org), 30.11.2022.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://derma.jmir.org" ext-link-type="uri">http://derma.jmir.org</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="derma_v5i4e38783.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://derma.jmir.org/2022/4/e38783"/><abstract><sec sec-type="background"><title>Background</title><p>Hidradenitis suppurativa (HS) is a potentially debilitating, chronic, recurring inflammatory disease. Observational databases provide opportunities to study the epidemiology of HS.</p></sec><sec sec-type="objective"><title>Objective</title><p>This study&#8217;s objective was to develop phenotype algorithms for HS suitable for epidemiological studies based on a network of observational databases.</p></sec><sec sec-type="methods"><title>Methods</title><p>A data-driven approach was used to develop 4 HS algorithms. A literature search identified prior HS algorithms. Standardized databases from the Observational Medical Outcomes Partnership (n=9) were used to develop 2 incident and 2 prevalent HS phenotype algorithms. Two open-source diagnostic tools, CohortDiagnostics and PheValuator, were used to evaluate and generate phenotype performance metric estimates, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value.</p></sec><sec sec-type="results"><title>Results</title><p>We developed 2 prevalent and 2 incident HS algorithms. Validation showed that PPV estimates were highest (mean 86%) for the prevalent HS algorithm requiring at least two HS diagnosis codes. Sensitivity estimates were highest (mean 58%) for the prevalent HS algorithm requiring at least one HS code.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This study illustrates the evaluation process and provides performance metrics for 2 incident and 2 prevalent HS algorithms across 9 observational databases. The use of a rigorous data-driven approach applied to a large number of databases provides confidence that the HS algorithms can correctly identify HS subjects.</p></sec></abstract><kwd-group><kwd>dermatology</kwd><kwd>hidradenitis suppurativa</kwd><kwd>medical dermatology</kwd><kwd>observational data</kwd><kwd>phenotype</kwd><kwd>inflammation</kwd><kwd>skin disease</kwd><kwd>epidemiology</kwd><kwd>algorithm</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory disease of the skin. Clinically, subjects have nodules, draining skin tunnels (ie, sinus tracts), abscesses, and bands of severe scar formation in the intertriginous skin areas, such as the axillary, groin, perianal, perineal, and inframammary regions [<xref rid="ref1" ref-type="bibr">1</xref>]. Patients with HS suffer from metabolic, psychiatric, and autoimmune disorders [<xref rid="ref2" ref-type="bibr">2</xref>].</p><p>The use of real-world evidence from observational data is valuable for studying the epidemiology, clinical manifestations, and real-world experience of patients with HS. A critical step in using observational data for the study of HS is the development of accurate phenotype algorithms (PAs). A PA is the translation of the case definition of a health condition or phenotype into an executable algorithm based on clinical data elements in a database [<xref rid="ref3" ref-type="bibr">3</xref>]. Several studies have investigated HS using health care claims, electronic medical records, patient care, and hospitalization databases and have been conducted using data from the United States, Germany, Finland, Taiwan, Korea, England, Canada, and Denmark [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref4" ref-type="bibr">4</xref>-<xref rid="ref32" ref-type="bibr">32</xref>]. These studies have focused on a range of topics in patients with HS, including the incidence and prevalence of HS in different populations and the associations between HS and autoimmune disorders. Only 5 studies have provided phenotype validation metrics [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]; 2 used hospital data [<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref29" ref-type="bibr">29</xref>], 4 used a single phenotype requiring at least one code for HS from the International Classification of Diseases, Ninth Revision (ICD-9) [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>], and 1 evaluated several phenotypes [<xref rid="ref16" ref-type="bibr">16</xref>].</p><p>The objectives of this study were to develop HS PAs, evaluate their performance, and characterize the resultant HS phenotypes across a network of 9 US and non-US observational databases. This study used a data-driven framework and developed HS PAs for use in observational databases.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Overview</title><p>A literature search was conducted to identify studies that describe the codes and logic used to identify HS patients in observational databases. This literature search identified 30 articles, which provided a set of diagnosis codes for the identification of HS across vocabularies, including the ICD-9, the International Classification of Diseases, Tenth Revision (ICD-10), and Read codes. Five of the 30 articles included validation metrics. Our study utilized the Systemized Nomenclature of Medicine (SNOMED) vocabulary to develop the codes. The vocabulary and diagnostic codes used in the published studies and the SNOMED terms are presented in <xref rid="app1" ref-type="supplementary-material">Multimedia Appendix 1</xref>. The Observational Health Data Sciences and Informatics (OHDSI) open-source Atlas tool [<xref rid="ref33" ref-type="bibr">33</xref>] was used to create the HS PAs.</p><p>The observational databases used in this study were not created specifically to study HS. The observational data were obtained in the delivery of health care or for administrative or billing purposes in electronic format. A network of 9 observational databases (4 administrative claims databases from the United States, 1 from Japan, 1 from France, 1 from Germany, and 1 from Australia; and 1 US electronic health record [EHR] database; <xref rid="table1" ref-type="table">Table 1</xref>) were used to develop the PAs. The 9 databases were a mix of administrative insurance claims, EHRs, and general practitioner databases. Descriptions and details of each database are shown in <xref rid="table2" ref-type="table">Table 2</xref>. The databases were transformed to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (version 5.3.1) [<xref rid="ref34" ref-type="bibr">34</xref>] so the PAs could be consistently applied across databases.</p><p>Four HS PAs were developed and evaluated in subjects of all ages [<xref rid="ref35" ref-type="bibr">35</xref>] (<xref rid="figure1" ref-type="fig">Figure 1</xref>). The PA &#8220;incident 1x&#8221; used the first diagnosis code for HS in a subject&#8217;s history and required 365 days of prior continuous enrollment (CE) time to qualify for entry into the HS cohort. The date a subject met both criteria was the subject&#8217;s index date. The PA &#8220;incident 2x&#8221; used the first diagnosis code for HS in a subject&#8217;s history and required both a second HS diagnosis code within 31 to 365 days and 365 days of prior CE time. The date a subject met all 3 criteria became the subject&#8217;s index date. The prevalent PAs (&#8220;prevalent 1x&#8221; and &#8220;prevalent 2x&#8221;) were identical to the corresponding incident versions, except that the first HS diagnosis code was not required to be the first time an HS code occurred in a subject&#8217;s history, nor was there a requirement for 365 days prior CE.</p><p>The OHDSI CohortDiagnostics tool [<xref rid="ref36" ref-type="bibr">36</xref>] allowed for evaluation and comparison of PAs at a cohort level, providing overall counts, incidence over time, the diagnosis code that allowed the subject into the cohort, cohort overlap, and temporal characterization.</p><p>Use of the PheValuator [<xref rid="ref37" ref-type="bibr">37</xref>] method provided performance metrics, including the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) associated with each PA. PheValuator is a machine learning&#8211;based method of assessing PAs. It constructs a predictive model for the disease and calculates the predictive value of having the disease for each subject using the model. Using PheValuator, performance indices of an algorithm are calculated without reviewing medical charts. While algorithm validation results from chart review are considered the &#8220;gold standard,&#8221; we have compared the results from PheValuator with prior studies using chart review and found excellent agreement between the 2 methods [<xref rid="ref38" ref-type="bibr">38</xref>]. Four additional PAs from Kim et al [<xref rid="ref16" ref-type="bibr">16</xref>] were evaluated for comparison.</p><p>Computer code for PheValuator and CohortDiagnostics and the JSON files for the PAs are available on the authors&#8217; website [<xref rid="ref39" ref-type="bibr">39</xref>].</p><table-wrap position="float" id="table1" orientation="portrait"><label>Table 1</label><caption><p>Description of databases used in the study.</p></caption><table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1"><col width="180" span="1"/><col width="90" span="1"/><col width="70" span="1"/><col width="150" span="1"/><col width="100" span="1"/><col width="90" span="1"/><col width="120" span="1"/><col width="90" span="1"/><col width="110" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Name</td><td rowspan="1" colspan="1">Years</td><td rowspan="1" colspan="1">Country</td><td rowspan="1" colspan="1">Data type</td><td rowspan="1" colspan="1">Clinical visits included</td><td rowspan="1" colspan="1">Subjects, n (millions)</td><td rowspan="1" colspan="1">Age at first observation, average (years)</td><td rowspan="1" colspan="1">Female subjects, %</td><td rowspan="1" colspan="1">Length of follow-up, median (years)</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">IBM MarketScan Commercial Claims and Encounters</td><td rowspan="1" colspan="1">2000-2021</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">Insurance claims</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">157</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">1.56</td></tr><tr valign="top"><td rowspan="1" colspan="1">IBM MarketScan Multi-State Medicaid</td><td rowspan="1" colspan="1">2006-2020</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">Insurance claims</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">1.52</td></tr><tr valign="top"><td rowspan="1" colspan="1">IBM MarketScan Medicare Supplemental</td><td rowspan="1" colspan="1">2000-2021</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">Insurance claims</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">2.46</td></tr><tr valign="top"><td rowspan="1" colspan="1">Optum&#8217;s de-identified Clinformatics Data Mart Database</td><td rowspan="1" colspan="1">2007-2021</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">Insurance claims</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">1.48</td></tr><tr valign="top"><td rowspan="1" colspan="1">Optum Electronic Health Records</td><td rowspan="1" colspan="1">2007-2021</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">Electronic health records</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">2.63</td></tr><tr valign="top"><td rowspan="1" colspan="1">Japan Medical Data Center</td><td rowspan="1" colspan="1">2000-2021</td><td rowspan="1" colspan="1">Japan</td><td rowspan="1" colspan="1">Insurance claims</td><td rowspan="1" colspan="1">Inpatient/outpatient</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">3.29</td></tr><tr valign="top"><td rowspan="1" colspan="1">IQVIA Disease Analyzer&#8211;France</td><td rowspan="1" colspan="1">2016-2021</td><td rowspan="1" colspan="1">France</td><td rowspan="1" colspan="1">General practitioner data</td><td rowspan="1" colspan="1">Outpatient</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">0.9</td></tr><tr valign="top"><td rowspan="1" colspan="1">IQVIA Disease Analyzer&#8211;Germany</td><td rowspan="1" colspan="1">2011-2021</td><td rowspan="1" colspan="1">Germany</td><td rowspan="1" colspan="1">General practitioner data with supplemental data from participating specialists</td><td rowspan="1" colspan="1">Outpatient</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">0.5</td></tr><tr valign="top"><td rowspan="1" colspan="1">IQVIA Australian Longitudinal Patient Data</td><td rowspan="1" colspan="1">1996-2020</td><td rowspan="1" colspan="1">Australia</td><td rowspan="1" colspan="1">General practitioner data</td><td rowspan="1" colspan="1">Outpatient</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">22<sup>a</sup></td><td rowspan="1" colspan="1">0.5</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>59% of subjects did not have a designated sex in this study.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="figure1" orientation="portrait"><label>Figure 1</label><caption><p>Schematics of phenotype algorithms for Hidradenitis suppurativa (HS).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="derma_v5i4e38783_fig1.jpg"/></fig></sec><sec><title>Ethics Approval</title><p>The use of the IBM and Clinformatics databases was reviewed by the New England Institutional Review Board and was determined to be exempt from broad approval, as this project did not involve human subject research. Patient consent for publication was not required. All patients in the databases were deidentified, and the identities of data contributors were removed.</p></sec></sec><sec sec-type="results"><title>Results</title><p>We examined cohort characteristics of the PAs. These characteristics may be viewed interactively online [<xref rid="ref40" ref-type="bibr">40</xref>]. The number of subjects ranged from 81 in the IQVIA Australian Longitudinal Patient Data (IALPD) database to 170,149 in the IBM MarketScan Commercial Claims and Encounters (CCAE) database for the incident 1x cohort. These numbers were as expected based on the relative sizes of the databases, indicating that all codes used were appropriate for each database. The counts were much higher in the US databases compared to the non-US databases. The reduction in the number of subjects in the incident 1x PA compared to the incident 2x PA ranged from about 90% in the IALPD, IQVIA Disease Analyzer&#8211;France (IDAF), and IQVIA Disease Analyzer&#8211;Germany (IDAG) databases to about 73% in the IBM MarketScan Multi-State Medicaid (MDCD) database. The incident 1x PA identified a higher proportion of female subjects compared to male subjects: 51% in the Japan Medical Data Center (JMDC) database and 81% in the MDCD database; the incident 2x PA identified a lower proportion of female subjects in the JMDC database (46%) but a higher proportion in all other databases, ranging from 53% for the IDAG database to 82% for the MDCD database. The overlap in subjects between the incident PAs for each database is shown in <xref rid="figure2" ref-type="fig">Figure 2</xref>. The incident 2x PA is a subset of the incident 1x PA.</p><p>A comparison of standardized differences between the incident 1x and the incident 2x cohorts for 3 data sets across 5 different time frames is shown in <xref rid="figure3" ref-type="fig">Figure 3</xref>. Differences in the standardized difference of the mean greater than 0.1 are considered imbalanced [<xref rid="ref41" ref-type="bibr">41</xref>]. Points closer to the diagonal indicate similar proportions between cohorts; points farther from the diagonal indicate more disparate proportions. The plots compare the diagnosed conditions, prescribed drugs, laboratory measurements, and clinical procedures of the subjects in the incident 1x and incident 2x PA cohorts and illustrate the population differences. The CCAE database showed disparities between the 2 algorithms in the period 31 to 365 days after the index date. Some differences arose from higher proportions of diagnosis codes for HS (50% for incident 2x vs 11% for incident 1x, standard mean difference [SMD] 0.66) and prescriptions for clindamycin (32% for incident 2x vs 14% for incident 1x, SMD 0.3). There were also differences in the MDCD database population, with more subjects of a lower socioeconomic status. The MDCD database also showed differences in diagnosis codes for HS (70% for incident 2x vs 18% for incident 1x, SMD 0.86) and prescriptions for clindamycin (37% for incident 2x vs 13% for incident 1x, SMD 0.31). The Optum&#8217;s de-identified Clinformatics Data Mart Database (Clinformatics DOD) data set showed differences in proportions between the 2 cohorts for diagnosis codes for HS (62% for incident 2x vs 14% for incident 1x, SMD 0.81) and prescriptions for clindamycin (29% for incident 2x vs 13% for incident 1x, SMD 0.29). The relative proportions between the 2 cohorts for the majority of the characteristics in the CCAE, MDCD, and Clinformatics DOD databases showed similar proportions between the cohorts.</p><p>We examined the incident 2x algorithm for subject characteristics across the databases. We identified a higher proportion of female subjects with HS compared to male subjects. The largest disproportionality was in the MDCD database, in which 82% of the subjects were female. The JMDC database had the lowest disproportionality by sex, with 45% female subjects. An outpatient visit was the most common type of clinical visit for the first diagnosis of HS. Less than 5% of first diagnoses were made during an emergency room visit, with the exception of the MDCD database, for which the proportion was 10%. Examination of the index codes or diagnosis codes that allowed subjects into cohorts showed that the most prevalent code was the diagnosis code of &#8220;hidradenitis suppurativa&#8221; (SNOMED code 4241223; ICD-10 L73.2) in all databases except the CCAE database, in which the most prevalent code was a diagnosis code of &#8220;hidradenitis&#8221; (SNOMED code 434119; ICD-9 705.83).</p><fig position="float" id="figure2" orientation="portrait"><label>Figure 2</label><caption><p>Graphical depiction of the overlap in subjects between the 2 incidence cohorts and the 2 prevalence cohorts. CCAE: IBM MarketScan Commercial Claims and Encounters; Clinformatics DOD: Optum&#8217;s de-identified Clinformatics Data Mart Database; IALPD: IQVIA Australian Longitudinal Patient Data; IDAF: IQVIA Disease Analyzer&#8211;France; IDAG: IQVIA Disease Analyzer&#8211;Germany; JMDC: Japan Medical Data Center; MDCD: IBM MarketScan Multi-State Medicaid; MDCR: IBM MarketScan Medicare Supplemental; Optum EHR: Optum Electronic Health Records.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="derma_v5i4e38783_fig2.jpg"/></fig><fig position="float" id="figure3" orientation="portrait"><label>Figure 3</label><caption><p>Comparison of the proportion of subjects in the incident 1x cohort and the incident 2x cohort for 3 selected data sets with different demographic characteristics. Points closer to the diagonal indicate similar proportions between the comparators; points farther from the diagonal indicate more disparate proportions. CCAE: IBM MarketScan Commercial Claims and Encounters; Clinformatics DOD: Optum&#8217;s de-identified Clinformatics Data Mart Database; MDCD: IBM MarketScan Multi-State Medicaid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="derma_v5i4e38783_fig3.jpg"/></fig><p>Incidence rates for HS (for the incident 2x algorithm) from 2015 to 2020 differed between databases. The MDCD database had the highest rate at 23 per 100,000 person-years. The rates in the CCAE, Clinformatics DOD, and Optum EHR databases were approximately 12 per 100,000 person-years. Rates in the IDAG and IDAF databases and the JMDC and the IBM MarketScan Medicare Supplemental Database (MDCR) databases were 1 per 100,000 person-years. The rate in the IALPD database was undetectable, likely due to the small sample size. The incidence rates peaked in subjects in the 20- to 29-year-old age group. The incidence rates in the 30- to 39-year-old age group in the MDCD and IDAG databases were higher than in the older age groups but were similar to the 20- to 29-year-old age group. Incidence rates in female subjects were generally higher than in male subjects and were highest in the MDCD database at 24 per 100,000 person-years, followed by 11 per 100,000 person-years in the CCAE, Clinformatics DOD, and Optum EHR databases and 1 per 100,000 person-years in the IDAF database. The rate in female subjects was equal to the rate in male subjects in the MDCR database at 2 per 100,000 person-years.</p><p>Performance characteristics for the HS phenotypes assessed using the PheValuator method are presented in <xref rid="table2" ref-type="table">Table 2</xref>. Due to low subject counts, calculation of performance characteristics for the IDAG, IDAF, IALPD, and JMDC databases was not possible. The mean PPVs were higher in all databases for the PAs requiring a second diagnostic HS code in the 31 to 365 days after the index date. The mean PPVs for the 2 PAs that required a second code was 88% (incident) and 86% (prevalent). This was reduced to 62% (incident) and 59% (prevalent) when only a single diagnosis code for HS was required. The highest sensitivity estimates were in the 2 prevalent cohorts. The sensitivity for the 2 prevalent algorithms was 58% (single code required) and 25% (2 codes required). This decreased to 32% (single code required) and 12% (2 codes required) in the incident cohorts. The estimates for mean PPV for the Kim et al [<xref rid="ref16" ref-type="bibr">16</xref>] PAs increased with the increase in number of HS diagnosis codes, ranging from 59% (2 codes) to 84% (5 codes). Our results showed a similar trend, but PPV was lower than reported by Kim et al (81% including subjects with 2 HS codes and 97% including subjects with &gt;5 codes).</p><table-wrap position="float" id="table2" orientation="portrait"><label>Table 2</label><caption><p>Performance characteristics of the hidradenitis suppurativa phenotypes based on the PheValuator methodology.</p></caption><table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1"><col width="30" span="1"/><col width="330" span="1"/><col width="160" span="1"/><col width="0" span="1"/><col width="160" span="1"/><col width="0" span="1"/><col width="160" span="1"/><col width="0" span="1"/><col width="160" span="1"/><thead><tr valign="bottom"><td colspan="2" rowspan="1">Phenotype algorithm/database</td><td colspan="2" rowspan="1">Sensitivity (95% CI)</td><td colspan="2" rowspan="1">PPV<sup>a</sup> (95% CI)</td><td colspan="2" rowspan="1">Specificity (95% CI)</td><td rowspan="1" colspan="1">NPV<sup>b</sup> (95% CI)</td></tr></thead><tbody><tr valign="top"><td colspan="9" rowspan="1">
<bold>Hidradenitis suppurativa incidence</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Commercial Database</td><td rowspan="1" colspan="1">0.380 (0.367-0.393)</td><td colspan="2" rowspan="1">0.599 (0.582-0.615)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum&#8217;s de-identified Clinformatics Data Mart Database</td><td rowspan="1" colspan="1">0.369 (0.358-0.380)</td><td colspan="2" rowspan="1">0.603 (0.589-0.617)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td><td colspan="2" rowspan="1">0.998 (0.997-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Multi-State Medicaid Database</td><td rowspan="1" colspan="1">0.311 (0.306-0.317)</td><td colspan="2" rowspan="1">0.676 (0.668-0.685)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td><td colspan="2" rowspan="1">0.990 (0.990-0.990)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Medicare Supplemental Database</td><td rowspan="1" colspan="1">0.298 (0.277-0.319)</td><td colspan="2" rowspan="1">0.444 (0.417-0.472)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum&#8217;s de-identified Electronic Health Record dataset</td><td rowspan="1" colspan="1">0.279 (0.269-0.289)</td><td colspan="2" rowspan="1">0.777 (0.761-0.793)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.997 (0.997-0.997)</td></tr><tr valign="top"><td colspan="9" rowspan="1">
<bold>Hidradenitis suppurativa incidence with second diagnosis 31 to 365 days after index date</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Commercial Database</td><td rowspan="1" colspan="1">0.151 (0.142-0.161)</td><td colspan="2" rowspan="1">0.890 (0.868-0.909)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum&#8217;s de-identified Clinformatics Data Mart Database</td><td rowspan="1" colspan="1">0.133 (0.126-0.141)</td><td colspan="2" rowspan="1">0.882 (0.862-0.900)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.997 (0.996-0.997)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Multi-State Medicaid Database</td><td rowspan="1" colspan="1">0.115 (0.112-0.119)</td><td colspan="2" rowspan="1">0.874 (0.862-0.885)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.987 (0.987-0.987)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Medicare Supplemental Database</td><td rowspan="1" colspan="1">0.109 (0.095-0.123)</td><td colspan="2" rowspan="1">0.830 (0.778-0.874)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum de-identified Electronic Health Record dataset</td><td rowspan="1" colspan="1">0.109 (0.102-0.116)</td><td colspan="2" rowspan="1">0.948 (0.931-0.962)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.997 (0.996-0.997)</td></tr><tr valign="top"><td colspan="9" rowspan="1">
<bold>Hidradenitis suppurativa prevalence</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Commercial Database</td><td rowspan="1" colspan="1">0.541 (0.531-0.551)</td><td colspan="2" rowspan="1">0.649 (0.639-0.660)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum&#8217;s de-identified Clinformatics Data Mart Database</td><td rowspan="1" colspan="1">0.666 (0.655-0.677)</td><td colspan="2" rowspan="1">0.602 (0.591-0.613)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Multi-State Medicaid Database</td><td rowspan="1" colspan="1">0.664 (0.658-0.670)</td><td colspan="2" rowspan="1">0.628 (0.621-0.634)</td><td colspan="2" rowspan="1">0.995 (0.995-0.995)</td><td colspan="2" rowspan="1">0.996 (0.996-0.996)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Medicare Supplemental Database</td><td rowspan="1" colspan="1">0.442 (0.422-0.462)</td><td colspan="2" rowspan="1">0.355 (0.338-0.373)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum de-identified Electronic Health Record dataset</td><td rowspan="1" colspan="1">0.632 (0.618-0.647)</td><td colspan="2" rowspan="1">0.754 (0.739-0.768)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td colspan="9" rowspan="1">
<bold>Hidradenitis suppurativa prevalence with second diagnosis 31 to 365 days after index date</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Commercial Database</td><td rowspan="1" colspan="1">0.296 (0.285-0.307)</td><td colspan="2" rowspan="1">0.874 (0.860-0.887)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.997 (0.997-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum&#8217;s de-identified Clinformatics Data Mart Database</td><td rowspan="1" colspan="1">0.233 (0.220-0.246)</td><td colspan="2" rowspan="1">0.937 (0.920-0.951)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.998 (0.998-0.998)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Multi-State Medicaid Database</td><td rowspan="1" colspan="1">0.219 (0.203-0.236)</td><td colspan="2" rowspan="1">0.732 (0.699-0.764)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IBM MarketScan Medicare Supplemental Database</td><td rowspan="1" colspan="1">0.288 (0.282-0.294)</td><td colspan="2" rowspan="1">0.859 (0.851-0.867)</td><td colspan="2" rowspan="1">0.999 (0.999-0.999)</td><td colspan="2" rowspan="1">0.992 (0.992-0.992)</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Optum de-identified Electronic Health Record dataset</td><td rowspan="1" colspan="1">0.231 (0.222-0.239)</td><td colspan="2" rowspan="1">0.912 (0.900-0.923)</td><td colspan="2" rowspan="1">1.000 (1.000-1.000)</td><td colspan="2" rowspan="1">0.996 (0.996-0.996)</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>PPV: positive predictive value.</p></fn><fn id="table2fn2"><p><sup>b</sup>NPV: negative predictive value.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Principal Findings</title><p>This study sought to develop and determine the accuracy of 4 HS PAs. The 4 PAs included 2 for incidence and 2 for prevalence, with one in each group having high sensitivity and specificity. Use of the PheValuator method allowed for estimation of sensitivity, specificity, PPV, and NPV without manual chart review. While both the incident and prevalent PAs were useful for the exploration of HS in observational databases, the PAs with definitions requiring just a single HS diagnosis code had lower specificity and higher sensitivity than the definitions requiring 2 codes, which had higher specificity and lower sensitivity. Thus, the choice of which algorithm to use is dependent on the research question being explored. For example, the use of a more sensitive algorithm would be applicable for safety studies, in which the PA is used to determine HS outcomes and missed identification of possible cases is problematic, whereas the use of a PA with higher specificity would be useful for treatment comparison studies, in which the goal is to ensure that all subjects exposed to a treatment have a high probability of having HS.</p><p>A few studies have included validation metrics for HS algorithms for observational databases [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]. Kim et al [<xref rid="ref16" ref-type="bibr">16</xref>] used data available from the Massachusetts General Hospital and reported an increase in PPV with an increasing number of HS diagnosis codes (81% for 2 codes vs 97% for 5 codes). Our study replicated the Kim et al cohorts and found an increase in PPV with the use of 5 or more diagnosis codes compared to the use of at least two HS diagnosis codes (mean 84% for &gt;5 codes vs mean 59% for 2 codes) that was similar to, albeit lower than, the published results. In general, our study found higher PPVs compared to studies that used a single HS diagnosis code [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]. The majority of subjects identified in our study were female, which is similar to findings from other studies [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref31" ref-type="bibr">31</xref>]. A US study that used a cross-sectional design and a large electronic medical records database found an overall prevalence of 24.8% for type 2 diabetes, 71.6% for obesity, and 39.9% for hyperlipidemia among HS subjects [<xref rid="ref8" ref-type="bibr">8</xref>]. Our study, when restricted to US data and examining covariates 365 days prior to and including the index date, identified type 2 diabetes in 26.5%, obesity in 19.6%, and hyperlipidemia in 26.5% of incident 1x HS subjects. The cross-sectional study was restricted to subjects aged 18 years or older, while our study included all ages, which may help in interpreting the decreased proportion of hyperlipidemia observed in our results. It has been reported that administrative databases underreport obesity as a diagnosis and are not an optimal data source for obesity prevalence [<xref rid="ref42" ref-type="bibr">42</xref>]. This may support our finding of a lower prevalence of obesity compared to the findings of the cross-sectional study.</p><p>Strengths of our study include the use of a rigorous, data-driven approach for generating and evaluating the HS phenotypes across a data network that included 9 databases covering US and non-US countries. Network-based phenotype evaluations greatly strengthen the knowledge base for a given algorithm, because they allow the assessment of the consistency of findings across data types, geographic locations, and time periods. When concordant trends emerge, it increases confidence that the observations are the effect of the PA itself rather than an artifact of a particular data source. The PAs were analyzed using multiple approaches, providing ancillary verification of decisions made in determining the cohort logic. Our study includes several study artifacts, including JSON files for the PAs, computer code, and results for all the analyzed PAs, providing transparency in our interpretation of the results.</p><p>There were also several limitations to our study. We used administrative data sets primarily maintained for insurance billing, which are well-known to have significant deficits, including coding inaccuracies [<xref rid="ref43" ref-type="bibr">43</xref>]. In addition, the estimation of performance characteristics using the PheValuator methodology was dependent on the quality of the data in the data set, which can vary substantially [<xref rid="ref37" ref-type="bibr">37</xref>]. The algorithm validation was performed using a method involving predictive modeling of HS rather than case reviews. Results from PheValuator have been compared to results from previously published validation studies and have demonstrated excellent agreement [<xref rid="ref38" ref-type="bibr">38</xref>]. This method does have the advantage of using multiple databases to provide a full set of performance metrics, including sensitivity and specificity, which are rarely provided in validation studies using case reviews [<xref rid="ref37" ref-type="bibr">37</xref>]. The generalizability of our findings to uninsured populations is uncertain, given the insured population that was observed in this study. In the incident PA that defined HS with only a single diagnosis code, it was not possible to determine if any of these were &#8220;rule-out&#8221; diagnoses. The algorithms presented in this study use codes specific to HS; therefore, jurisdictions and practices that do not use these specific codes and instead use codes for &#8220;abscess&#8221; or &#8220;cyst&#8221; would be unable to operationalize these PAs. The study period used for evaluation of the HS algorithms includes the year (2015) when the drug Humira was introduced to treat HS [<xref rid="ref44" ref-type="bibr">44</xref>]. Education on HS increased, and physicians became more likely to use diagnosis codes specifically indicating HS in observational data. Therefore, to avoid temporal bias, researchers should avoid use of these algorithms in data from prior to 2015.</p></sec><sec><title>Conclusions</title><p>This study developed and evaluated 4 HS PAs using a rigorous, data-driven approach and generated phenotype performance metrics including sensitivity, specificity, PPV, and NPV. Based on the analyses, we recommend that PAs requiring a single HS diagnosis code be used in studies requiring high sensitivity, while studies requiring high specificity should use PAs requiring 2 HS diagnosis codes. These algorithms will enable researchers to use large observational databases to research HS, which has a high burden of disease. There is a need for better evidence, as currently there are clinical knowledge gaps for HS that observational data is well suited to address.</p></sec></sec></body><back><ack><p>Manuscript review was provided by Anna Sheahan, PhD. All authors contributed to all aspects of the study (study design and execution, data analysis and interpretation, and writing of the manuscript). This research was funded by Janssen Research and Development, LLC. The data source for this study was a retrospective claims database and thus there are no patient or public contributors.</p></ack><fn-group><fn fn-type="COI-statement"><p>Conflicts of Interest: All authors are employees of Janssen Research and Development, LLC, and may own stock or stock options. The work performed for this study was part of their employment.</p></fn></fn-group><app-group><supplementary-material id="app1" position="float" content-type="local-data" orientation="portrait"><label>Multimedia Appendix 1</label><p>Diagnostic codes.</p><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="derma_v5i4e38783_app1.docx" xlink:title="DOCX File , 15 KB" id="d95e996" position="anchor" orientation="portrait"/></supplementary-material></app-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">CCAE</term><def><p>IBM MarketScan Commercial Claims and Encounters</p></def></def-item><def-item><term id="abb2">CE</term><def><p>continuous enrollment</p></def></def-item><def-item><term id="abb3">Clinformatics DOD</term><def><p>Optum&#8217;s de-identified Clinformatics Data Mart Database</p></def></def-item><def-item><term id="abb4">EHR</term><def><p>electronic health record</p></def></def-item><def-item><term id="abb5">HS</term><def><p>hidradenitis suppurativa</p></def></def-item><def-item><term id="abb6">IALPD</term><def><p>IQVIA Australian Longitudinal Patient Data</p></def></def-item><def-item><term id="abb7">ICD-9</term><def><p>International Classification of Diseases, Ninth Revision</p></def></def-item><def-item><term id="abb8">ICD-10</term><def><p>International Classification of Diseases, Tenth Revision</p></def></def-item><def-item><term id="abb9">IDAF</term><def><p>IQVIA Disease Analyzer&#8211;France</p></def></def-item><def-item><term id="abb10">IDAG</term><def><p>IQVIA Disease Analyzer&#8211;Germany</p></def></def-item><def-item><term id="abb11">JMDC</term><def><p>Japan Medical Data Center</p></def></def-item><def-item><term id="abb12">MDCD</term><def><p>IBM MarketScan Multi-State Medicaid</p></def></def-item><def-item><term id="abb13">MDCR</term><def><p>IBM MarketScan Medicare Supplemental</p></def></def-item><def-item><term id="abb14">NPV</term><def><p>negative predictive value</p></def></def-item><def-item><term id="abb15">OHDSI</term><def><p>Observational Health Data Sciences and Informatics</p></def></def-item><def-item><term id="abb16">OMOP</term><def><p>Observational Medical Outcomes Partnership</p></def></def-item><def-item><term id="abb17">PA</term><def><p>phenotype algorithm</p></def></def-item><def-item><term id="abb18">PPV</term><def><p>positive predictive value</p></def></def-item><def-item><term id="abb19">SMD</term><def><p>standard mean difference</p></def></def-item><def-item><term id="abb20">SNOMED</term><def><p>Systemized Nomenclature of Medicine</p></def></def-item></def-list></glossary><notes><sec sec-type="data-availability"><title>Data Availability</title><p>The data used for this study are proprietary and only available through a licensing data-use agreement process. This process ensures that confidentiality of the data contributors is maintained and that the data are used appropriately. The MarketScan Research Database can be licensed by researchers.</p></sec></notes><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alikhan</surname><given-names>A</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>DB</given-names></name></person-group><article-title>Hidradenitis suppurativa: a comprehensive review</article-title><source>J Am Acad Dermatol</source><year>2009</year><month>04</month><volume>60</volume><issue>4</issue><fpage>539</fpage><lpage>61; quiz 562</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.11.911</pub-id><pub-id pub-id-type="medline">19293006</pub-id><pub-id pub-id-type="pii">S0190-9622(09)00036-X</pub-id><pub-id pub-id-type="pmid">19293006</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiri</surname><given-names>H</given-names></name><name name-style="western"><surname>Jokelainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Timonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Tasanen</surname><given-names>K</given-names></name><name name-style="western"><surname>Huilaja</surname><given-names>L</given-names></name></person-group><article-title>Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents</article-title><source>J Am Acad Dermatol</source><year>2018</year><month>09</month><volume>79</volume><issue>3</issue><fpage>514</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.02.067</pub-id><pub-id pub-id-type="medline">29518461</pub-id><pub-id pub-id-type="pii">S0190-9622(18)30353-0</pub-id><pub-id pub-id-type="pmid">29518461</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overby</surname><given-names>CL</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>J</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>O</given-names></name><name name-style="western"><surname>Haerian</surname><given-names>K</given-names></name><name name-style="western"><surname>Perotte</surname><given-names>A</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Talwalkar</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>S</given-names></name><name name-style="western"><surname>Kullo</surname><given-names>I</given-names></name><name name-style="western"><surname>Chute</surname><given-names>C</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>C</given-names></name><name name-style="western"><surname>Bottinger</surname><given-names>E</given-names></name><name name-style="western"><surname>Hripcsak</surname><given-names>G</given-names></name><name name-style="western"><surname>Weng</surname><given-names>C</given-names></name></person-group><article-title>A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury</article-title><source>J Am Med Inform Assoc</source><year>2013</year><month>12</month><day>01</day><volume>20</volume><issue>e2</issue><fpage>e243</fpage><lpage>52</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/23837993" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1136/amiajnl-2013-001930</pub-id><pub-id pub-id-type="medline">23837993</pub-id><pub-id pub-id-type="pii">amiajnl-2013-001930</pub-id><pub-id pub-id-type="pmid">23837993</pub-id><pub-id pub-id-type="pmcid">PMC3861914</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Skup</surname><given-names>M</given-names></name><name name-style="western"><surname>Zueger</surname><given-names>P</given-names></name><name name-style="western"><surname>Garg</surname><given-names>V</given-names></name><name name-style="western"><surname>Panaccione</surname><given-names>R</given-names></name></person-group><article-title>Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study</article-title><source>Adv Ther</source><year>2019</year><month>07</month><day>17</day><volume>36</volume><issue>7</issue><fpage>1672</fpage><lpage>1683</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/31102202" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1007/s12325-019-00964-z</pub-id><pub-id pub-id-type="medline">31102202</pub-id><pub-id pub-id-type="pii">10.1007/s12325-019-00964-z</pub-id><pub-id pub-id-type="pmid">31102202</pub-id><pub-id pub-id-type="pmcid">PMC6824390</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosmatos</surname><given-names>I</given-names></name><name name-style="western"><surname>Matcho</surname><given-names>A</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>MO</given-names></name><name name-style="western"><surname>Stang</surname><given-names>P</given-names></name></person-group><article-title>Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States</article-title><source>J Am Acad Dermatol</source><year>2013</year><month>03</month><volume>68</volume><issue>3</issue><fpage>412</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2012.07.027</pub-id><pub-id pub-id-type="medline">22921795</pub-id><pub-id pub-id-type="pii">S0190-9622(12)00812-2</pub-id><pub-id pub-id-type="pmid">22921795</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>N</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P</given-names></name></person-group><article-title>High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics</article-title><source>Br J Dermatol</source><year>2017</year><month>04</month><day>21</day><volume>176</volume><issue>4</issue><fpage>1048</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1111/bjd.14976</pub-id><pub-id pub-id-type="medline">27534703</pub-id><pub-id pub-id-type="pmid">27534703</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egeberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Gislason</surname><given-names>GH</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>PR</given-names></name></person-group><article-title>Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa</article-title><source>JAMA Dermatol</source><year>2016</year><month>04</month><volume>152</volume><issue>4</issue><fpage>429</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2015.6264</pub-id><pub-id pub-id-type="medline">26885728</pub-id><pub-id pub-id-type="pii">2491691</pub-id><pub-id pub-id-type="pmid">26885728</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name><name name-style="western"><surname>Birabaharan</surname><given-names>M</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>A</given-names></name></person-group><article-title>Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States</article-title><source>J Am Acad Dermatol</source><year>2018</year><month>07</month><volume>79</volume><issue>1</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.01.014</pub-id><pub-id pub-id-type="medline">29339240</pub-id><pub-id pub-id-type="pii">S0190-9622(18)30098-7</pub-id><pub-id pub-id-type="pmid">29339240</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lavian</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>A</given-names></name></person-group><article-title>Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States</article-title><source>JAMA Dermatol</source><year>2017</year><month>08</month><day>01</day><volume>153</volume><issue>8</issue><fpage>760</fpage><lpage>764</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/28492923" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1001/jamadermatol.2017.0201</pub-id><pub-id pub-id-type="medline">28492923</pub-id><pub-id pub-id-type="pii">2626146</pub-id><pub-id pub-id-type="pmid">28492923</pub-id><pub-id pub-id-type="pmcid">PMC5710402</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name><name name-style="western"><surname>Lavian</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>A</given-names></name><name name-style="western"><surname>Alloo</surname><given-names>A</given-names></name></person-group><article-title>Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis</article-title><source>J Am Acad Dermatol</source><year>2017</year><month>07</month><volume>77</volume><issue>1</issue><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2017.02.005</pub-id><pub-id pub-id-type="medline">28285782</pub-id><pub-id pub-id-type="pii">S0190-9622(17)30163-9</pub-id><pub-id pub-id-type="pmid">28285782</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>C</given-names></name><name name-style="western"><surname>Chien</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: A nationwide, population-based, cohort study in Taiwan</article-title><source>J Dermatol</source><year>2019</year><month>10</month><volume>46</volume><issue>10</issue><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.15038</pub-id><pub-id pub-id-type="medline">31389066</pub-id><pub-id pub-id-type="pmid">31389066</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingram</surname><given-names>J</given-names></name><name name-style="western"><surname>Jenkins-Jones</surname><given-names>S</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>D</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>C</given-names></name><name name-style="western"><surname>Cannings-John</surname><given-names>R</given-names></name><name name-style="western"><surname>Piguet</surname><given-names>V</given-names></name></person-group><article-title>Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa</article-title><source>Br J Dermatol</source><year>2018</year><month>04</month><volume>178</volume><issue>4</issue><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1111/bjd.16101</pub-id><pub-id pub-id-type="medline">29094346</pub-id><pub-id pub-id-type="pmid">29094346</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jemec</surname><given-names>GBE</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>Annie</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M</given-names></name></person-group><article-title>What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis</article-title><source>J Med Econ</source><year>2016</year><month>07</month><day>14</day><volume>19</volume><issue>7</issue><fpage>710</fpage><lpage>7</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tandfonline.com/doi/full/10.3111/13696998.2016.1161636" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3111/13696998.2016.1161636</pub-id><pub-id pub-id-type="medline">26938967</pub-id><pub-id pub-id-type="pmid">26938967</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MW</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Won</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WJ</given-names></name></person-group><article-title>Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa</article-title><source>JAMA Dermatol</source><year>2020</year><month>08</month><day>01</day><volume>156</volume><issue>8</issue><fpage>844</fpage><lpage>853</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/32459291" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1001/jamadermatol.2020.1422</pub-id><pub-id pub-id-type="medline">32459291</pub-id><pub-id pub-id-type="pii">2766018</pub-id><pub-id pub-id-type="pmid">32459291</pub-id><pub-id pub-id-type="pmcid">PMC7254443</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalsa</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>JS</given-names></name></person-group><article-title>Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa</article-title><source>J Am Acad Dermatol</source><year>2015</year><month>10</month><volume>73</volume><issue>4</issue><fpage>609</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2015.06.053</pub-id><pub-id pub-id-type="medline">26190241</pub-id><pub-id pub-id-type="pii">S0190-9622(15)01859-9</pub-id><pub-id pub-id-type="pmid">26190241</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Shlyankevich</surname><given-names>J</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>A</given-names></name></person-group><article-title>The validity of the diagnostic code for hidradenitis suppurativa in an electronic database</article-title><source>Br J Dermatol</source><year>2014</year><month>08</month><volume>171</volume><issue>2</issue><fpage>338</fpage><lpage>42</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/24712395" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1111/bjd.13041</pub-id><pub-id pub-id-type="medline">24712395</pub-id><pub-id pub-id-type="pmid">24712395</pub-id><pub-id pub-id-type="pmcid">PMC4219870</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>G</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>Annie</given-names></name><name name-style="western"><surname>Pivneva</surname><given-names>I</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>A</given-names></name></person-group><article-title>The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis</article-title><source>Dermatol Ther (Heidelb)</source><year>2018</year><month>12</month><volume>8</volume><issue>4</issue><fpage>557</fpage><lpage>569</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/30306395" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1007/s13555-018-0264-z</pub-id><pub-id pub-id-type="medline">30306395</pub-id><pub-id pub-id-type="pii">10.1007/s13555-018-0264-z</pub-id><pub-id pub-id-type="pmid">30306395</pub-id><pub-id pub-id-type="pmcid">PMC6261111</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirby</surname><given-names>JS</given-names></name><name name-style="western"><surname>Miller</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Adams</surname><given-names>DR</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>D</given-names></name></person-group><article-title>Health care utilization patterns and costs for patients with hidradenitis suppurativa</article-title><source>JAMA Dermatol</source><year>2014</year><month>09</month><volume>150</volume><issue>9</issue><fpage>937</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2014.691</pub-id><pub-id pub-id-type="medline">24908260</pub-id><pub-id pub-id-type="pii">1878305</pub-id><pub-id pub-id-type="pmid">24908260</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>N</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hagenstr&#246;m</surname><given-names>K</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach</article-title><source>J Eur Acad Dermatol Venereol</source><year>2020</year><month>01</month><volume>34</volume><issue>1</issue><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/jdv.15940</pub-id><pub-id pub-id-type="medline">31494987</pub-id><pub-id pub-id-type="pmid">31494987</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J</given-names></name></person-group><article-title>Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2018</year><month>10</month><volume>32</volume><issue>10</issue><fpage>1784</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1111/jdv.15071</pub-id><pub-id pub-id-type="medline">29761904</pub-id><pub-id pub-id-type="pmid">29761904</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marvel</surname><given-names>J</given-names></name><name name-style="western"><surname>Vlahiotis</surname><given-names>A</given-names></name><name name-style="western"><surname>Sainski-Nguyen</surname><given-names>A</given-names></name><name name-style="western"><surname>Willson</surname><given-names>T</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>A</given-names></name></person-group><article-title>Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data</article-title><source>BMJ Open</source><year>2019</year><month>09</month><day>30</day><volume>9</volume><issue>9</issue><fpage>e030579</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bmjopen.bmj.com/lookup/pmidlookup?view=long&amp;pmid=31575575" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1136/bmjopen-2019-030579</pub-id><pub-id pub-id-type="medline">31575575</pub-id><pub-id pub-id-type="pii">bmjopen-2019-030579</pub-id><pub-id pub-id-type="pmcid">PMC6797383</pub-id><pub-id pub-id-type="pmid">31575575</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMillan</surname><given-names>Kathleen</given-names></name></person-group><article-title>Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States</article-title><source>Am J Epidemiol</source><year>2014</year><month>06</month><day>15</day><volume>179</volume><issue>12</issue><fpage>1477</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/aje/kwu078</pub-id><pub-id pub-id-type="medline">24812161</pub-id><pub-id pub-id-type="pii">kwu078</pub-id><pub-id pub-id-type="pmid">24812161</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehdizadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosella</surname><given-names>L</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sibbald</surname><given-names>G</given-names></name><name name-style="western"><surname>Farzanfar</surname><given-names>D</given-names></name><name name-style="western"><surname>Hazrati</surname><given-names>A</given-names></name><name name-style="western"><surname>Vernich</surname><given-names>L</given-names></name><name name-style="western"><surname>Laporte</surname><given-names>A</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Bashash</surname><given-names>M</given-names></name></person-group><article-title>A Canadian population-based cohort to the study cost and burden of surgically resected hidradenitis suppurativa</article-title><source>J Cutan Med Surg</source><year>2018</year><volume>22</volume><issue>3</issue><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1177/1203475418763536</pub-id><pub-id pub-id-type="medline">29528753</pub-id><pub-id pub-id-type="pmid">29528753</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>S</given-names></name><name name-style="western"><surname>Singam</surname><given-names>V</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Amin</surname><given-names>A</given-names></name><name name-style="western"><surname>Silverberg</surname><given-names>J</given-names></name></person-group><article-title>Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: a cross-sectional analysis of the National Inpatient Sample</article-title><source>Br J Dermatol</source><year>2019</year><month>08</month><volume>181</volume><issue>2</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/bjd.17416</pub-id><pub-id pub-id-type="medline">30422314</pub-id><pub-id pub-id-type="pmid">30422314</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinter</surname><given-names>A</given-names></name><name name-style="western"><surname>Kokolakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Rech</surname><given-names>J</given-names></name><name name-style="western"><surname>Biermann</surname><given-names>MHC</given-names></name><name name-style="western"><surname>H&#228;berle</surname><given-names>Benjamin M</given-names></name><name name-style="western"><surname>Multmeier</surname><given-names>J</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>M</given-names></name></person-group><article-title>Hidradenitis suppurativa and concurrent psoriasis: comparison of epidemiology, comorbidity profiles, and risk factors</article-title><source>Dermatol Ther (Heidelb)</source><year>2020</year><month>08</month><volume>10</volume><issue>4</issue><fpage>721</fpage><lpage>734</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/32500484" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1007/s13555-020-00401-y</pub-id><pub-id pub-id-type="medline">32500484</pub-id><pub-id pub-id-type="pii">10.1007/s13555-020-00401-y</pub-id><pub-id pub-id-type="pmid">32500484</pub-id><pub-id pub-id-type="pmcid">PMC7367943</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Rodriguez</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Timerman</surname><given-names>D</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>L</given-names></name><name name-style="western"><surname>Hunjan</surname><given-names>MK</given-names></name><name name-style="western"><surname>Lemor</surname><given-names>A</given-names></name></person-group><article-title>The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014</article-title><source>Int J Dermatol</source><year>2018</year><month>05</month><volume>57</volume><issue>5</issue><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1111/ijd.13932</pub-id><pub-id pub-id-type="medline">29431201</pub-id><pub-id pub-id-type="pmid">29431201</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>QZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>BT</given-names></name><name name-style="western"><surname>Fukudome</surname><given-names>EY</given-names></name></person-group><article-title>Surgical management of hidradenitis suppurativa: procedural trends and risk factors</article-title><source>J Surg Res</source><year>2018</year><month>09</month><volume>229</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2018.04.007</pub-id><pub-id pub-id-type="medline">29936991</pub-id><pub-id pub-id-type="pii">S0022-4804(18)30246-4</pub-id><pub-id pub-id-type="pmid">29936991</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeweiss</surname><given-names>M</given-names></name><name name-style="western"><surname>Merola</surname><given-names>J</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>S</given-names></name><name name-style="western"><surname>Wyss</surname><given-names>R</given-names></name><name name-style="western"><surname>Rosmarin</surname><given-names>D</given-names></name></person-group><article-title>Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa</article-title><source>J Eur Acad Dermatol Venereol</source><year>2021</year><month>01</month><volume>35</volume><issue>1</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/jdv.16728</pub-id><pub-id pub-id-type="medline">32531094</pub-id><pub-id pub-id-type="pmid">32531094</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shlyankevich</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GE</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name></person-group><article-title>Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis</article-title><source>J Am Acad Dermatol</source><year>2014</year><month>12</month><volume>71</volume><issue>6</issue><fpage>1144</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2014.09.012</pub-id><pub-id pub-id-type="medline">25440440</pub-id><pub-id pub-id-type="pii">S0190-9622(14)01912-4</pub-id><pub-id pub-id-type="pmid">25440440</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strunk</surname><given-names>A</given-names></name><name name-style="western"><surname>Midura</surname><given-names>M</given-names></name><name name-style="western"><surname>Papagermanos</surname><given-names>V</given-names></name><name name-style="western"><surname>Alloo</surname><given-names>A</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name></person-group><article-title>Validation of a case-finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database</article-title><source>Dermatology</source><year>2017</year><volume>233</volume><issue>1</issue><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1159/000468148</pub-id><pub-id pub-id-type="medline">28448975</pub-id><pub-id pub-id-type="pii">000468148</pub-id><pub-id pub-id-type="pmid">28448975</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzellos</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mu</surname><given-names>F</given-names></name><name name-style="western"><surname>Calimlim</surname><given-names>B</given-names></name><name name-style="western"><surname>Signorovitch</surname><given-names>J</given-names></name></person-group><article-title>Impact of hidradenitis suppurativa on work loss, indirect costs and income</article-title><source>Br J Dermatol</source><year>2019</year><month>07</month><volume>181</volume><issue>1</issue><fpage>147</fpage><lpage>154</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/30120887" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1111/bjd.17101</pub-id><pub-id pub-id-type="medline">30120887</pub-id><pub-id pub-id-type="pmid">30120887</pub-id><pub-id pub-id-type="pmcid">PMC7379487</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertenteil</surname><given-names>S</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>A</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name></person-group><article-title>Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa</article-title><source>J Am Acad Dermatol</source><year>2019</year><month>05</month><volume>80</volume><issue>5</issue><fpage>1308</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.09.040</pub-id><pub-id pub-id-type="medline">30287328</pub-id><pub-id pub-id-type="pii">S0190-9622(18)32651-3</pub-id><pub-id pub-id-type="pmid">30287328</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="webpage"><article-title>Atlas</article-title><source>GitHub</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/OHDSI/Atlas" ext-link-type="uri">https://github.com/OHDSI/Atlas</ext-link></comment></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overhage</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>PB</given-names></name><name name-style="western"><surname>Reich</surname><given-names>CG</given-names></name><name name-style="western"><surname>Hartzema</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stang</surname><given-names>PE</given-names></name></person-group><article-title>Validation of a common data model for active safety surveillance research</article-title><source>J Am Med Inform Assoc</source><year>2012</year><volume>19</volume><issue>1</issue><fpage>54</fpage><lpage>60</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/22037893" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1136/amiajnl-2011-000376</pub-id><pub-id pub-id-type="medline">22037893</pub-id><pub-id pub-id-type="pii">amiajnl-2011-000376</pub-id><pub-id pub-id-type="pmid">22037893</pub-id><pub-id pub-id-type="pmcid">PMC3240764</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="webpage"><article-title>OHDSI/PhenotypeEvaluations/tree/main/HS/inst/cohorts</article-title><source>GitHub</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/OHDSI/PhenotypeEvaluations/tree/main/HS/inst/cohorts" ext-link-type="uri">https://github.com/OHDSI/PhenotypeEvaluations/tree/main/HS/inst/cohorts</ext-link></comment></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="webpage"><article-title>CohortDiagnostics | Introduction</article-title><source>GitHub</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/OHDSI/CohortDiagnostics" ext-link-type="uri">https://github.com/OHDSI/CohortDiagnostics</ext-link></comment></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swerdel</surname><given-names>JN</given-names></name><name name-style="western"><surname>Hripcsak</surname><given-names>G</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>PB</given-names></name></person-group><article-title>PheValuator: Development and evaluation of a phenotype algorithm evaluator</article-title><source>J Biomed Inform</source><year>2019</year><month>09</month><volume>97</volume><fpage>103258</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1532-0464(19)30177-7" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.jbi.2019.103258</pub-id><pub-id pub-id-type="medline">31369862</pub-id><pub-id pub-id-type="pii">S1532-0464(19)30177-7</pub-id><pub-id pub-id-type="pmid">31369862</pub-id><pub-id pub-id-type="pmcid">PMC7736922</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swerdel</surname><given-names>JN</given-names></name><name name-style="western"><surname>Schuemie</surname><given-names>M</given-names></name><name name-style="western"><surname>Murray</surname><given-names>G</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>PB</given-names></name></person-group><article-title>PheValuator 2.0: Methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation</article-title><source>J Biomed Inform</source><year>2022</year><month>11</month><volume>135</volume><fpage>104177</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1532-0464(22)00188-5" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.jbi.2022.104177</pub-id><pub-id pub-id-type="medline">35995107</pub-id><pub-id pub-id-type="pii">S1532-0464(22)00188-5</pub-id><pub-id pub-id-type="pmid">35995107</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="webpage"><article-title>OHDSI/PhenotypeEvaluations/tree/main/HS</article-title><source>GitHub</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/OHDSI/PhenotypeEvaluations/tree/main/HS" ext-link-type="uri">https://github.com/OHDSI/PhenotypeEvaluations/tree/main/HS</ext-link></comment></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="webpage"><article-title>Cohort Definition</article-title><source>OHDSI Cohort Diagnostics</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.ohdsi.org/HSCohortDiagnostics" ext-link-type="uri">https://data.ohdsi.org/HSCohortDiagnostics</ext-link></comment></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austin</surname><given-names>PC</given-names></name></person-group><article-title>Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research</article-title><source>Commun Stat Simul Comput</source><year>2009</year><month>04</month><day>09</day><volume>38</volume><issue>6</issue><fpage>1228</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1080/03610910902859574</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Graham</surname><given-names>M</given-names></name><name name-style="western"><surname>Quan</surname><given-names>H</given-names></name></person-group><article-title>Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies</article-title><source>BMC Health Serv Res</source><year>2014</year><month>02</month><day>13</day><volume>14</volume><fpage>70</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-14-70" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/1472-6963-14-70</pub-id><pub-id pub-id-type="medline">24524687</pub-id><pub-id pub-id-type="pii">1472-6963-14-70</pub-id><pub-id pub-id-type="pmid">24524687</pub-id><pub-id pub-id-type="pmcid">PMC3996078</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyree</surname><given-names>PT</given-names></name><name name-style="western"><surname>Lind</surname><given-names>BK</given-names></name><name name-style="western"><surname>Lafferty</surname><given-names>WE</given-names></name></person-group><article-title>Challenges of using medical insurance claims data for utilization analysis</article-title><source>Am J Med Qual</source><year>2006</year><volume>21</volume><issue>4</issue><fpage>269</fpage><lpage>75</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/16849784" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1177/1062860606288774</pub-id><pub-id pub-id-type="medline">16849784</pub-id><pub-id pub-id-type="pii">21/4/269</pub-id><pub-id pub-id-type="pmid">16849784</pub-id><pub-id pub-id-type="pmcid">PMC1533763</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="webpage"><article-title>Humira (adalimumab) | A Biologic Treatment Option</article-title><source>AbbVie Inc</source><date-in-citation content-type="access-date">2022-11-16</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.humira.com/" ext-link-type="uri">https://www.humira.com/</ext-link></comment></element-citation></ref></ref-list></back></article></pmc-articleset>